A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021)

NCT05939648 | Unknown Phase 2 DMC

• 1 other identifier: LVRNA021-II-01
• Study Type: interventional
• Target: 450
• Locations: 1 country
• Sites: 1

Brief Summary

This trial is a phase II clinical trial of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021). The trial was randomized, blinded, placebo controlled. To evaluate the safety and immunogenicity of the study vaccine in participants aged 18 years and older who have received SARS-CoV-2 Vaccine.

Conditions

SARS-CoV-2

Outcome Measures

Primary Outcomes (2)

• GMT and SCR of live virus neutralizing antibodys against SARS-CoV-2 (Delta strain, Omicron BA.5, XBB strains and current major circulating strains).

  GMT and SCR of live virus neutralizing antibodys against SARS-CoV-2 ( Delta strain, Omicron BA.5, XBB strains and current major circulating strains) on day 14 after vaccination.

  14 day after booster vaccination.

• Incidence of solicited and unsolicited adverse events

  Incidence of solicited and unsolicited adverse events within 0-28 days after booster vaccination.

  0-28 days after booster vaccination.

Secondary Outcomes (6)

• Incidence of serious adverse events (SAEs) and adverse events of special interests (AESIs).

  12 months after booster vaccination

• GMI of live virus neutralizing antibodies against SARS-CoV-2 (Delta strain, Omicron BA.5, XBB strains and current major circulating strains).

  14 day after booster vaccination.

• GMT, SCR, GMI of live virus neutralizing antibodies against SARS-CoV-2 (Delta strain, Omicron BA.5, XBB strains and current major circulating strains).

  7, 28 days after booster vaccination.

• GMT of live virus neutralizing antibodies against SARS-CoV-2 (Delta strain, Omicron BA.5, XBB strains and current major circulating strains).

  3, 6, 12 months after booster vaccination.

• GMC, SCR, GMI of IgG antibodies against S proteins of SARS-CoV-2 ( Delta strain, Omicron BA.5)

  7, 14, 28 days after booster vaccination.

Other Outcomes (1)

• Specific T cell responses after booster vaccination.

  7, 14, 28 days after booster vaccination.

Study Arms (2)

SARS-CoV-2 Bivalent mRNA Vaccine

EXPERIMENTAL

100 μg /1.0 mL/dose, One booster dose 1.0mL IM injection of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021).

Biological: SARS-CoV-2 Bivalent mRNA Vaccine

Saline

PLACEBO COMPARATOR

One booster dose 1.0mL IM injection of saline.

Other: Saline

Interventions

SARS-CoV-2 Bivalent mRNA Vaccine BIOLOGICAL

100 μg /1.0 mL/dose, slightly milky white and clear liquid, intramuscular injection into the lateral deltoid muscle of the upper arm.

Also known as: LVRNA021

SARS-CoV-2 Bivalent mRNA Vaccine

Saline OTHER

100 μg /1.0 mL/dose, intramuscular injection into the lateral deltoid muscle of the upper arm.

Saline

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Healthy adults aged 18 years and older, both male and female, who can provide legal identity certificate of participants;
• The subject understands the contents of the Informed Consent Form and the vaccination situation of this vaccination, voluntarily signs the Informed Consent Form, and has the ability to use the thermometer, scale and fill in the Diary Card and Contact Card as required (if the subject is unable to sign the Informed Consent Form by himself/herself due to limited reading and writing ability, the informed consent form and signature of the Informed Consent Form can be completed under the witness' s witness);
• Able to communicate well with investigators and understand and comply with the requirements of this trial;
• Completion of basic immunization with SARS-CoV-2 vaccine ≥ 6 months;
• Negative nucleic acid test for SARS-CoV-2 within 3 days prior to vaccination;

You may not qualify if:

• Participants with abnormal electrocardiogram during screening and who were judged unsuitable for vaccination by investigators; Blood pressure indicators during the screening period: systolic blood pressure ≥160 or diastolic blood pressure ≥100mmHgHg, or abnormal blood pressure, and the health status determined by the investigator is uncertain and requires further diagnosis, or the investigator determines that the vaccination is not suitable for participants with medical history and clinical manifestations ;
• Body mass index (BMI) \<18 kg/m 2 or \>30 kg/m 2;
• Individuals with any infectious disease, acute infection, acute phase of chronic infection (such as active untreated pulmonary tuberculosis, etc.) or any advanced immune disease (inquiry);
• Infected within last 6 months or likely infected with SARS-CoV-2;
• Positive HIV test result at screening;
• Fever on the day of investigational vaccination (axillary temperature ≥ 37.3℃) or within 3 days, or use of antipyretic and analgesic drugs within 3 days;
• Women with a positive pregnancy test (surgical sterilizers who are menstruating or amenorrheic for at least 1 year or have medical records may be exempted from pregnancy testing), or breastfeeding women, or women planning to become pregnant from screening through 6 months after booster vaccination, men whose partners plan to become pregnant, or plan to donate sperm and eggs;
• Previous history of allergic or allergic reactions to vaccines or drugs, such as urticaria, severe skin eczema, dyspnea, laryngeal edema, angioneurotic edema, etc.;
• Administration of any vaccine within 28 days prior to booster vaccination with investigational vaccine;
• Have participated within 28 days prior to booster vaccination with investigational vaccine or plan to participate in other drug clinical trials within 12 months after booster vaccination;
• Patients with a history of thrombocytopenia or other coagulation disorders, which may cause contraindications to subcutaneous blood sampling or injection, and patients with a history of thrombosis;
• Known history or diagnosis of diseases affecting immune system function, such as cancer (except basal cell carcinoma of the skin), congenital or acquired immunodeficiency, uncontrolled autoimmune diseases, etc. (such as systemic lupus erythematosus, autoimmune thyroid disease, multiple sclerosis);
• Absence of spleen or functional absence of spleen;
• Chronic use (≥14 consecutive days) of immunosuppressants or other immunomodulatory drugs (eg, corticosteroids: prednisone or drugs of the same class) within 6 months prior to booster vaccination with the investigational vaccine, but topical medications (eg, ointments, eye drops, inhalers, or nasal sprays) are allowed and should not exceed the dose recommended in the package insert;
• Immunoglobulins and/or blood products received within 3 months prior to the investigational booster vaccination;

Sponsors & Collaborators

• AIM Vaccine Co., Ltd.: lead
• Ningbo Rongan Biological Pharmaceutical Co., Ltd.: collaborator

Study Sites (1)

Chuanmiao Liu

Bengbu, Anhui, China

Location

MeSH Terms

Interventions

Sodium Chloride

Intervention Hierarchy (Ancestors)

Chlorides; Hydrochloric Acid; Chlorine Compounds; Inorganic Chemicals; Sodium Compounds

Study Officials

• Fan Zhang

  AIM Vaccine Co., Ltd.

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 7, 2023
• First Posted: July 11, 2023
• Study Start: October 9, 2023
• Primary Completion: November 30, 2023
• Study Completion: December 30, 2024
• Last Updated: November 24, 2023

Record last verified: 2023-11

Locations

CN (1)